The Yield Paradox: Turning Strict Protocols into Recruitment Success: In clinical development, recruitment is often judged by volume. But the reality is a “Yield Paradox”: high applicant numbers frequently lead to low enrollment efficiency and site burnout.The Challenge: The “Eligibility Wall” In a recent early-stage breast cancer study, we saw this firsthand. While the trial […]

The Way Forward for Decentralise Clinical Trials in Japan: As Decentralized clinical trials, brings participants the opportunity of participating in a clinical trial from the ease of their home or a local healthcare facility which is different to the traditional clinical trial site location far from the participant’s home. 3H, a Home-based clinical trial leader […]

Initiating the provision of analysis information on differences in drug effects for each genetic polymorphism for contributing to the advancement of drug development and improvement in treatment options and treatment satisfaction for patients. 3H Medi Solution Inc. (Toshima-ku, Tokyo; CEO: Hirotaka Takizawa) and Genequest Inc. (Minato-ku, Tokyo; CEO: Osamu Iwata) have jointly conducted an analysis […]

The world is transitioning into the information age in healthcare and modern digital health technologies have a lot to offer in optimising clinical trial conduct. The advent of wearable medical devices has enabled collection of multi-dimensional subject data. This has enabled de-centralisation of clinical trial conduct. 3H has been agile to adopt the latest information […]

Clinical trial conduct is a substantial investment requiring the right mix of resources and time. With the pharmaceutical industry facing many challenges in the Western world due to escalating costs and challenges in meeting the recruitment and retention of subjects, there is a trend in navigating clinical trial options in the Asian continent. Contract research […]

Supporting clinical trial patients at home is getting popular choice today in Japan following this pandemic. The need for decentralized clinical trials in Japan has increased, as measures have been implemented to prevent the re-emergence of the outbreak and streamline the systems used to run clinical trials. Unless mandatory, clinical trial patients are served in […]